Online ISSN: 2515-8260

Keywords : non

Regression of Lumbar Disc Herniation Following Non-surgical Treatment

Eric Chun-Pu Chu; Divya Midhun Chakkaravarthy; Fa-Sain Lo; Amiya Bhaumik

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 1, Pages 27-29

Symptomatic disc herniation is the most common disc pathology and can result in substantial disability and poor quality of life. Here, we present a male patient who was diagnosed as having lumbar disc herniation at L3/L4 and L4/L5 levels with nerve root entrapment. The patient sought chiropractic treatment for severe back pain which lead to trouble walking. After 7 months of a medical/chiropractic intervention, complete pain relief and recovery of muscle weakness were achieved. At 11-month follow-up, the regression of the herniated discs was documented on MR imaging. This case presentation aims to raise a reappraisal of our knowledge of intervertebral disc herniation in regard to the natural history, the components of herniated material and possible mechanisms behind hernia regression, which holds the key to treating this problem. Through the translation of research evidence into practice, current guidelines recalibrate instructions on the diagnosis and treatment of symptomatic disc herniation.

Improvement of adherence to treatment in patients with nonmuscle invasive bladder cancer (NMIBC) by spreading the 12 months maintenance Bacillus Calmette-Guerin (BCG) regimen over 18 months

Rani Zreik; Boris Friedman; Nitza Hirshberg; Gal Rinott Mizrahi; Yael Hod; Ghazi Fari; Freifeld Yuval; Avi Stein; Yoram Dekel

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 1, Pages 30-34

Purpose - To evaluate what effect spreading the maintenance BCG regimen from 12 to 18 months has on the treatment completion rate. Patients and methods - Retrospective data about patients diagnosed with intermediate or high risk nonmuscle invasive bladder cancer were collected. Suggested regimen started with 6 weekly induction intravesical full dose BCG instillations followed by 3 weekly instillations, 3 months after the 6th instillation. Thereafter, 3 weekly instillations were delivered 6 months after the 9th and the 12th instillation. In total, 15 BCG instillations were administered within 18 months. Cystoscopy and urine cytology were performed one month following the 6th, 9th, 12th and 15th instillations and then according to guidelines Results - 195 patients met the inclusion criteria. 190 (97.4%) patients completed the induction instillations and 141 (72.3%) completed the treatment protocol. 39 patients discontinued treatment for medical reasons and 15 patients due to non-compliance. 162 patients completed follow up as recommended for a median of 46±20.1 months. Of those, 45 patients (27.8%) and 8 (4.9%) had disease recurrence and progression, respectively. Conclusion - Spreading BCG instillations during maintenance protocol might achieve a better treatment completion rate, mainly due to improved patient compliance. No impacts on recurrence and progression rates have been observed in our cohort. Prospective randomized trials are warranted before suggesting clinical application.

Satellite symposium: Emerging role of microwave imaging technology (organized by the biomedicine and molecular biosciences COST action TD1301) Microwave Imaging for Breast Cancer Detection

Martin O’Halloran

European Journal of Molecular & Clinical Medicine, 2015, Volume 2, Issue 2, Pages -

Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. This represents about 12% of all new cancer cases and 25% of all cancers in women. The current standard method for detecting non-palpable early stage breast cancer is X-ray mammography. Despite the fact that X-rays provide high-resolution images at low radiation doses, its limitations are well documented. In the U.S., up to 75% of all malignancies identified by X-ray mammography are later found to be benign after biopsies. These false positive conclusions result in unnecessary biopsies, causing considerable distress to the patient and an unnecessary financial burden on the health service. Much more worryingly, up to 15% of all breast cancers present at the time of screening are missed by conventional mammography, often delaying treatment to the point where it’s no longer effective.